129 related articles for article (PubMed ID: 38859770)
21. Two Cases of Renal Cell Carcinoma Harboring a Novel STRN-ALK Fusion Gene.
Kusano H; Togashi Y; Akiba J; Moriya F; Baba K; Matsuzaki N; Yuba Y; Shiraishi Y; Kanamaru H; Kuroda N; Sakata S; Takeuchi K; Yano H
Am J Surg Pathol; 2016 Jun; 40(6):761-9. PubMed ID: 26848800
[TBL] [Abstract][Full Text] [Related]
22. Primary resistance to alectinib in a patient with STRN-ALK-positive non-small cell lung cancer: A case report.
Sun K; Nie L; Nong L; Cheng Y
Thorac Cancer; 2021 Jun; 12(12):1927-1930. PubMed ID: 33960639
[TBL] [Abstract][Full Text] [Related]
23. High STRN Expression Promotes HCC Invasion and Migration but Not Cell Proliferation or Apoptosis through Facilitating Epithelial-Mesenchymal Transition.
Du QY; Yao JH; Zhou YC; Xu LJ; Zhao FY; Yang Y
Biomed Res Int; 2020; 2020():6152925. PubMed ID: 32280692
[TBL] [Abstract][Full Text] [Related]
24. Characterization of thyroid cancer driven by known and novel ALK fusions.
Panebianco F; Nikitski AV; Nikiforova MN; Kaya C; Yip L; Condello V; Wald AI; Nikiforov YE; Chiosea SI
Endocr Relat Cancer; 2019 Nov; 26(11):803-814. PubMed ID: 31539879
[TBL] [Abstract][Full Text] [Related]
25. Clinical Utility of Cell-Free DNA for the Detection of
McCoach CE; Blakely CM; Banks KC; Levy B; Chue BM; Raymond VM; Le AT; Lee CE; Diaz J; Waqar SN; Purcell WT; Aisner DL; Davies KD; Lanman RB; Shaw AT; Doebele RC
Clin Cancer Res; 2018 Jun; 24(12):2758-2770. PubMed ID: 29599410
[No Abstract] [Full Text] [Related]
26. A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.
Zeng H; Liu Y; Wang W; Tang Y; Tian P; Li W
Ann Palliat Med; 2021 Jul; 10(7):8352-8357. PubMed ID: 33832282
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer.
Xiang Y; Zhang S; Fang X; Jiang Y; Fang T; Liu J; Lu K
Curr Oncol; 2022 Oct; 29(10):7816-7831. PubMed ID: 36290895
[TBL] [Abstract][Full Text] [Related]
28. Identification of novel ALK fusions using DNA/RNA sequencing in immunohistochemistry / RT-PCR discordant NSCLC patients.
Wang B; Chen R; Wang C; Guo J; Yuan M; Chen H; Xia X; Zhong D
Hum Pathol; 2021 Aug; 114():90-98. PubMed ID: 34019866
[TBL] [Abstract][Full Text] [Related]
29. Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target.
Yakirevich E; Resnick MB; Mangray S; Wheeler M; Jackson CL; Lombardo KA; Lee J; Kim KM; Gill AJ; Wang K; Gowen K; Sun J; Miller VA; Stephens PJ; Ali SM; Ross JS; Safran H
Clin Cancer Res; 2016 Aug; 22(15):3831-40. PubMed ID: 26933125
[TBL] [Abstract][Full Text] [Related]
30.
Nagasaka M; Sarvadevabatla N; Iwata S; Ge Y; Sukari A; Klosowski C; Yanagihara R
JTO Clin Res Rep; 2021 Feb; 2(2):100125. PubMed ID: 34589985
[No Abstract] [Full Text] [Related]
31.
Bastos AU; de Jesus AC; Cerutti JM
Eur J Endocrinol; 2018 Jan; 178(1):83-91. PubMed ID: 29046324
[TBL] [Abstract][Full Text] [Related]
32.
Bulutay P; Vatansever D; Taskiran C; Mericoz CA; Tokat F; Kapucuoglu N; Kulac I
Indian J Pathol Microbiol; 2023; 66(2):392-395. PubMed ID: 37077094
[TBL] [Abstract][Full Text] [Related]
33. Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations.
Yang X; Zhong J; Yu Z; Zhuo M; Zhang M; Chen R; Xia X; Zhao J
BMC Cancer; 2021 Oct; 21(1):1107. PubMed ID: 34654390
[TBL] [Abstract][Full Text] [Related]
34. Identification and Development of a Lung Adenocarcinoma PDX Model With STRN-ALK Fusion.
Ren H; Hou X; Eiken PW; Zhang J; Pierson KE; Nair AA; Davila JI; Kovarikova H; Jang JS; Johnson SH; Molina JR; Marks RS; Yang P; Yi JE; Mansfield AS; Jen J
Clin Lung Cancer; 2019 Mar; 20(2):e142-e147. PubMed ID: 30581091
[No Abstract] [Full Text] [Related]
35. STRN-ALK rearranged pediatric malignant peritoneal mesothelioma - Functional testing of 527 cancer drugs in patient-derived cancer cells.
Murumägi A; Ungureanu D; Arjama M; Bützow R; Lohi J; Sariola H; Kanerva J; Koskenvuo M; Kallioniemi O
Transl Oncol; 2021 Apr; 14(4):101027. PubMed ID: 33530027
[TBL] [Abstract][Full Text] [Related]
36. Detection of STRN-ALK fusion in thyroid nodules with indeterminate cytopathology facilitates papillary thyroid cancer diagnosis.
Jurkiewicz M; Cimic A; Murty VV; Kuo JH; Hsiao S; Fazlollahi L; Fernandes H
Diagn Cytopathol; 2021 Apr; 49(4):E146-E151. PubMed ID: 33085842
[TBL] [Abstract][Full Text] [Related]
37. [STRN::ALK fusion renal cell carcinoma with lung metastasis: report of a case].
Xian J; Yin XX; Wang DH; Zhang MX; Zheng LM; Zhou Q; Chen N
Zhonghua Bing Li Xue Za Zhi; 2024 Jun; 53(6):631-633. PubMed ID: 38825915
[TBL] [Abstract][Full Text] [Related]
38. Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.
Hung YP; Dong F; Watkins JC; Nardi V; Bueno R; Dal Cin P; Godleski JJ; Crum CP; Chirieac LR
JAMA Oncol; 2018 Feb; 4(2):235-238. PubMed ID: 28910456
[TBL] [Abstract][Full Text] [Related]
39. Identification of novel ALK rearrangement A2M-ALK in a neonate with fetal lung interstitial tumor.
Onoda T; Kanno M; Sato H; Takahashi N; Izumino H; Ohta H; Emura T; Katoh H; Ohizumi H; Ohtake H; Asao H; Dehner LP; Hill AD; Hayasaka K; Mitsui T
Genes Chromosomes Cancer; 2014 Oct; 53(10):865-74. PubMed ID: 24965693
[TBL] [Abstract][Full Text] [Related]
40. A review of ALK-rearranged renal cell carcinomas with a focus on clinical and pathobiological aspects.
Kuroda N; Sugawara E; Kusano H; Yuba Y; Yorita K; Takeuchi K
Pol J Pathol; 2018; 69(2):109-113. PubMed ID: 30351856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]